RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+2.83%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.31B
AUM Growth
+$3.31B
(-16%)
Cap. Flow
-$387M
Cap. Flow
% of AUM
-11.67%
Top 10 Holdings %
Top 10 Hldgs %
35.65%
Holding
121
New
8
Increased
41
Reduced
28
Closed
10
Top Buys
| 1 |
Insmed
INSM
|
$54.2M |
| 2 |
Johnson & Johnson
JNJ
|
$24.8M |
| 3 |
Structure Therapeutics
GPCR
|
$23.1M |
| 4 |
UnitedHealth
UNH
|
$22.9M |
| 5 |
Eli Lilly
LLY
|
$16.5M |
Top Sells
| 1 |
Immunocore
IMCR
|
$66M |
| 2 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$44M |
| 3 |
Penumbra
PEN
|
$43.2M |
| 4 |
Boston Scientific
BSX
|
$32M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$31.1M |
Sector Composition
| 1 | Healthcare | 97.63% |
| 2 | Consumer Staples | 1.87% |
| 3 | Industrials | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
West Pharmaceutical
WST
$17.9B
| $47.9M | 1.44% |
145,500
+8,250
| +6% | +$2.72M |
|
|
27
Penumbra
PEN
$10.5B
| $47.7M | 1.44% |
265,000
-240,000
| -48% | -$43.2M |
|
28
Exact Sciences
EXAS
$9.33B
| $45.7M | 1.38% |
1,081,500
+21,750
| +2% | +$919K |
|
|
29
Agios Pharmaceuticals
AGIO
$2.36B
| $45M | 1.36% |
1,044,261
-720,244
| -41% | -$31.1M |
|
30
Sarepta Therapeutics
SRPT
$1.98B
| $44.9M | 1.35% |
284,000
-43,600
| -13% | -$6.89M |
|
31
iRhythm Technologies
IRTC
$5.67B
| $42.8M | 1.29% |
397,500
+5,250
| +1% | +$565K |
|
32
Ascendis Pharma
ASND
$12.1B
| $39.6M | 1.19% |
290,000
| – | – |
|
33
Insulet
PODD
$24.2B
| $39.4M | 1.18% |
195,000
-125,000
| -39% | -$25.2M |
|
|
34
Structure Therapeutics
GPCR
$1.14B
| $39.3M | 1.18% |
999,862
+587,213
| +142% | +$23.1M |
|
35
Travere Therapeutics
TVTX
$1.75B
| $36.8M | 1.11% |
4,482,265
+1,057,447
| +31% | +$8.69M |
|
36
Azenta
AZTA
$1.35B
| $36.6M | 1.1% |
696,000
+1,250
| +0.2% | +$65.8K |
|
37
Revolution Medicines
RVMD
$7.43B
| $36.6M | 1.1% |
943,195
+19,514
| +2% | +$757K |
|
38
Kymera Therapeutics
KYMR
$3.1B
| $34.7M | 1.05% |
1,163,973
-358,265
| -24% | -$10.7M |
|
|
MREO
39
Mereo BioPharma
MREO
$275M
| $33.4M | 1.01% |
9,283,492
+1,141,383
| +14% | +$4.11M |
|
40
Warby Parker
WRBY
$3.08B
| $33.4M | 1.01% |
2,080,000
| – | – |
|
41
Immunovant
IMVT
$2.91B
| $31.3M | 0.94% |
1,185,654
+35,531
| +3% | +$938K |
|
42
Align Technology
ALGN
$9.59B
| $30.8M | 0.93% |
127,500
-92,500
| -42% | -$22.3M |
|
43
Akero Therapeutics
AKRO
$3.65B
| $25.2M | 0.76% |
1,074,261
-225,627
| -17% | -$5.29M |
|
|
44
Johnson & Johnson
JNJ
$429B
| $24.8M | 0.75% |
+170,000
| New | +$24.8M |
|
45
Lifestance Health
LFST
$2.14B
| $23.7M | 0.71% |
4,827,700
+47,700
| +1% | +$234K |
|
46
Zai Lab
ZLAB
$3.48B
| $22.5M | 0.68% |
1,297,873
+750
| +0.1% | +$13K |
|
47
Pacira BioSciences
PCRX
$1.22B
| $22.5M | 0.68% |
785,000
-270,500
| -26% | -$7.74M |
|
48
Legend Biotech
LEGN
$6.64B
| $22.4M | 0.67% |
505,786
+6,300
| +1% | +$279K |
|
49
BioCryst Pharmaceuticals
BCRX
$1.74B
| $22.4M | 0.67% |
3,619,258
+123,002
| +4% | +$760K |
|
50
Novo Nordisk
NVO
$252B
| $21.1M | 0.63% |
147,500
| – | – |
|